QuantHealth secures strategic investment from Sanofi Ventures to enhance AI-driven clinical trials and drug development.

Oct 01, 2025•about 1 month ago

Amount Raised

$30 Million

Tel AvivBiotechnologyHealth Care

Investors

Sanofi Ventures

Description

QuantHealth announced a strategic investment from Sanofi Ventures to advance AI-powered digital twins and clinical trial simulations. This funding brings its total raised to $30 million. The investment will help improve trial success rates, timelines, and cost efficiency. Cris De Luca from Sanofi Ventures will join QuantHealth’s Board of Directors as an observer.

Company Information

Company

QuantHealth

Location

Tel Aviv, Tel Aviv District, Israel

About

QuantHealth is an AI company conducting patient-centric drug simulations to accelerate and de-risk drug development. Over 90% of drugs in clinical development stage fail to reach the market, which accumulates to a $45B/year direct lost to the pharma and biotech industry. Our platform allows our pharma and biotech partners to rapidly run thousands of variations of their clinical trials to optimize the trial design and significantly increase the probability of trial success, all while enabling discovery of new clinical opportunities and optimization strategies. QuantHealth has one the largest integrated datasets that spans the clinical, pharmacological and biological domains together with a proprietary AI platform that can predict patient-response to both approved and novel therapies.

Related People

0 contacts

No contacts found in Executives department

Try selecting a different department above

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends